Press Release

28 February 2017

HitGen and CRUK Enter Into Licence Agreement in Lung Cancer

Cancer Research UK, Cancer Research Technology (CRT), the charity’s commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
23 September 2016

Academician Sang Guowei Visits HitGen LTD

September 22, 2016, Chengdu – Academician Sang Guowei, the Vice Chairperson of the National People’s Congress of the Peoples’ Republic of China, Chief Engineer of National Major Innovative Drug Projects as well as an Academician of the Chinese Academy of Engineering, accompanied by officials from Sichuan Provincial and Chengdu Municipal Government visited HitGen Ltd. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to Professor Sang Guowei.
22 September 2016

HitGen Ltd. Collaborates with Johnson & Johnson

Chengdu, China, September 22, 2016, HitGen Ltd., a privately held biotech company focused on technology for effective and efficient molecular discovery, announced today a multi-target global collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has been facilitated by Johnson & Johnson Innovation. This collaboration is to discover potential new therapies in areas of strategic interest to Janssen, especially in the areas of oncology and metabolics.
23 August 2016

New Drug Discovery: Find Needles in Very Large Haystacks

Aug 23th, as the first speaker of 5th IAPC Meeting, Dr. Jin Li introduced the technical principle of DNA Encoded Library (DELs) synthesis and screening and its potential impact on the early new drug discovery, which attracted several attendees’ interest.
07 May 2016

Nature Biotechnology: DNA-encoded Drug Libraries Come of Age

May 6, 2016 – Nature Biotechnology published an article named “DNA-encoded Drug Libraries Come of Age”. In this article, it introduced the basic principles of DNA-encoded Libraries (DEL) and some major developments in innovative drug discoveries. It also gave recognition of contribution in innovative drug discoveries area made by those DEL companies at home and abroad including HitGen.
30 April 2016

Professor Richard A. Lerner and Professor K. Barry Sharpless Visit HitGen

April 29, 2016, Chengdu – HitGen had the honor to host Professor Richard A. Lerner, former President of The Scripps Research Institute and Professor K. Barry Sharpless (winner of the 2001 Nobel Prize in Chemistry for catalyzed oxidation reactions) visit our site in Chengdu. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to the guests. Later on, both sides held a deeper and comprehensive discussion based on companies’ technologies, development, etc.
26 April 2016

Premier Li Keqiang Speaks Highly of HitGen’s Giant “Innovative Drug

April 24, 2016 – HitGen, as a “high-tech pioneer” of biotechnology field in Sichuan Province, was inspected and encouraged by Premier Li Keqiang. The premier gave HitGen recognition on its rapid growth for the past 4 years and instructed HitGen urgently to translate the existing giant “Innovative Drug Discovery Library” to real innovative drugs that patients can use.
31 January 2016

HitGen Enters Into Research Collaboration with GBT

Chengdu, China January 8, 2016 – HitGen LtD, a privately held drug discovery company that enables the extraordinary power of DNA encoded libraries with a patented proprietary platform to discover new therapeutic starting points, announced today a research collaboration with Global Blood Therapeutics, Inc. (NASDAQ: GBT), a clinical-stage biopharmaceutical company dedicated to novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs. HitGen will provide biology, chemistry, and screening to support GBT’s efforts around an undisclosed novel target.
04 June 2015

Drug Discovery Deal Signed between HitGen and Tasly

Recently, Tasly Holding Group (Tasly, a major pharmaceutical company in China) held “Industry- Research-Investment Collaboration Signing Ceremony for its Big Health Project” in TianJin, China. In the event, Tasly signed 11 new drug discovery collaboration agreements with HitGen Ltd.(HitGen) and other 8 companies, research institutions. According to the agreement, HitGen will use its proprietary DNA Encoded Libraries to collaborate with Tasly. The collaboration has significant financial value.
17 April 2015

HitGen Announces Collaboration in Drug Discovery with Cyclofluidic Ltd

Chengdu, China, 17 April 2015– HitGen Ltd today announced that it has entered into research collaboration with Cyclofluidic Ltd, UK, using hits obtained from HitGen’s proprietary lead discovery technology. Within the framework of the collaboration, novel allosteric inhibitors of GSK3b, a kinase implicated in neurodegenerative diseases, will be optimised using CyclOpsTM technology to provide advanced leads suitable for clinical development.

News

Press Release

Thanks for reading!